Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
21.22
-0.32 (-1.49%)
At close: May 22, 2026, 4:00 PM EDT
21.87
+0.65 (3.04%)
After-hours: May 22, 2026, 7:00 PM EDT
Alto Neuroscience Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
68
Market Cap
743.82M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 210.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ARS Pharmaceuticals | 98.99M |
| Crescent Biopharma | 11.88M |
| Absci | 1.84M |
| Avalo Therapeutics | 59.00K |
| Allogene Therapeutics | 22.00K |
ANRO News
- 3 days ago - Alto Neuroscience price target lowered to $33 from $35 at BofA - TheFly
- 7 days ago - Alto Neuroscience price target lowered to $36 from $38 at Baird - TheFly
- 10 days ago - Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award - Business Wire
- 10 days ago - Alto Neuroscience price target raised to $24 from $21 at Wedbush - TheFly
- 11 days ago - Alto Neuroscience Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 12 days ago - Alto Neuroscience reports Q1 EPS (80c) vs (56c) last year - TheFly
- 12 days ago - Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights - Business Wire
- 12 days ago - Alto Neuroscience Earnings release: Q1 2026 - Filings